FDA approved Saphnelo (anifrolumab) for Moderate to Severe Systemic Lupus ErythematosusFDA approved new lupus drug Saphnelo for adults with moderate to severe disease.

FDA From the archive Source published July 30, 2021 Summary added August 13, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider Saphnelo for moderate to severe SLE, but avoid in severe active lupus nephritis or CNS lupus.

The U.S. Food and Drug Administration has approved Saphnelo (anifrolumab) for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. This approval provides a new biologic option targeting the type I interferon pathway, which is implicated in SLE pathogenesis. Saphnelo is the first drug approved specifically for SLE that blocks the type I interferon receptor.

The approval is based on clinical trials that demonstrated a reduction in disease activity compared to placebo, as measured by composite endpoints. However, the label notes that efficacy has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus, and use is not recommended in these situations. Clinicians should consider this limitation when selecting therapy.

Saphnelo is available in two formulations: intravenous infusion (300 mg every 4 weeks) and subcutaneous injection (120 mg once weekly). The subcutaneous formulation includes a prefilled syringe and an autoinjector (Saphnelo Pen). This flexibility may offer patients and providers options for administration, though the choice depends on patient preference and clinical circumstances.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Saphnelo (anifrolumab) is a type I interferon (IFN) receptor antagonist. It binds to the type I IFN receptor, thereby blocking the activity of type I interferons (e.g., IFN-alpha, IFN-beta, IFN-omega). This action reduces signaling through the type I IFN pathway, which is thought to contribute to the inflammatory processes in systemic lupus erythematosus.

Indication & Patient Population

Saphnelo is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Limitations of Use: The efficacy of Saphnelo has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of Saphnelo is not recommended in these situations.

Dosing & Administration

The recommended dosage of Saphnelo is either 300 mg administered as an intravenous infusion over 30 minutes every 4 weeks, or 120 mg administered as a subcutaneous injection once every week. For intravenous use, the vial must be diluted in 0.9% Sodium Chloride Injection, USP before infusion. For subcutaneous use, the prefilled syringe or autoinjector (Saphnelo Pen) is used. If a dose is missed, specific instructions are provided: for intravenous, administer as soon as possible with a minimum interval of 14 days between infusions; for subcutaneous, administer as soon as remembered and then start a new weekly schedule or resume on the usual day, with a minimum interval of 3 days between injections. When switching from intravenous to subcutaneous, administer the first subcutaneous injection approximately 2 weeks after the last intravenous infusion. When switching from subcutaneous to intravenous, follow the recommended intravenous dosing schedule.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

No contraindications are listed in the label. The label does not provide specific warnings beyond the limitations of use. It is recommended to avoid use in patients with severe active lupus nephritis or severe active central nervous system lupus due to lack of efficacy data.

Place in Therapy

Saphnelo is a new biologic option for adult patients with moderate to severe SLE who are on standard therapy. It targets the type I interferon pathway, offering a different mechanism of action compared to other SLE treatments. However, its use is not recommended in severe active lupus nephritis or severe active CNS lupus. Clinicians should consider the patient's clinical presentation and the limitations of the drug when determining its place in therapy.

The U.S. Food and Drug Administration (FDA) has approved a new medicine called Saphnelo (anifrolumab) for adults with moderate to severe systemic lupus erythematosus (SLE), commonly known as lupus. Lupus is an autoimmune disease where the immune system attacks healthy tissues, causing inflammation and damage. Saphnelo works by blocking a specific immune pathway (type I interferon) that is thought to play a role in lupus. It is the first drug approved for lupus that targets this pathway.

Saphnelo is for adults who are already receiving standard therapy for lupus, such as hydroxychloroquine or corticosteroids, but still have moderate to severe disease activity. In clinical trials, patients taking Saphnelo showed a reduction in disease activity compared to those on placebo. The drug is available in two forms: an intravenous infusion given every four weeks, and a subcutaneous injection (under the skin) given once a week. The injection comes as a prefilled syringe or an autoinjector pen, offering flexibility in how it is taken.

However, it is important to know that Saphnelo has not been studied in people with severe active lupus nephritis (kidney disease) or severe active central nervous system lupus. Therefore, it is not recommended for those situations. This approval provides a new treatment option, but it is not a cure, and it may not be right for everyone.

If you have lupus, talk to your doctor about whether Saphnelo might be a good option for you. Your doctor can help you weigh the potential benefits and risks based on your specific condition and treatment history.

What this means for you:

Saphnelo is a new lupus treatment, but it is not for everyone, so talk to your doctor.

Study Details

Study typeFda approval

PublishedJul 2021

View Original Abstract ↓

1 INDICATIONS AND USAGE SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. SAPHNELO is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. ( 1 ) Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. ( 1 )

FDA approved Saphnelo (anifrolumab) for Moderate to Severe Systemic Lupus ErythematosusFDA approved new lupus drug Saphnelo for adults with moderate to severe disease.

Study Details

Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management

Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms

Clinical research that matters. Delivered to your inbox.

FDA approved Saphnelo (anifrolumab) for Moderate to Severe Systemic Lupus ErythematosusFDA approved new lupus drug Saphnelo for adults with moderate to severe disease.

Study Details

Evaluating the Efficacy of Traditional Chinese Medicine Decoctions for Rheumatoid Arthritis Management

Traditional Chinese medicine decoctions may improve rheumatoid arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Related in Rheumatology

From Other Specialties